Bone Biologics Corporation

BBLG

We are a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration.

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$1M

EPS-$0.06

P/E-5.78

P/FCF-0.46

EV/EBITDA1.63

FCF Yield–

Div. Yield–

Net Debt/FCF2.4x

Bone Biologics Corporation intrinsic value

52-Week Range

$0.35$1.03

Profitability & Returns

TTM as of 2026-09 · YoY vs prior year · ROIC = NOPAT / invested capital

Revenue

N/A

Net Income (TTM)

-$3M

▲ +24.4% YoY

Op. Margin

–

ROIC

-47.78%

▲ +46.6pp YoY

Cash Flow & Balance Sheet

FCF = operating cash flow + capex · Net debt = total debt − cash · Balance sheet from latest filing

FCF (TTM)

-$3M

▲ +34.8% YoY

Op. Cash Flow (TTM)

-$3M

▲ +34.8% YoY

Net Debt

-$6M

Net Cash Position

Cash & Equiv.

$6M

Continue Research

Quality Scorecard

Is this a high-quality business?

Dividends

Payout safety and growth

Intrinsic Value

What is it worth?

Financials

Full income, cash flow, balance sheet

Peers

Orthopedic, Prosthetic & Surgical Appliances & Supplies · Pick stocks to compare with BBLG

CompareIntrinsic value

AVNSAvanos Medical Inc.

No recent price12

CDRECadre Holdings Inc.

$30.84-0.71%63

INGNInogen Inc.

$7.22+2.85%25

ESTAEstablishment Labs Holdings Inc.

$66.94+9.02%30

MSAMsa Safety Inc.

$177.60+2.03%75

LAKELakeland Industries Inc.

$8.93-0.11%15

SMTISanara MedTech Inc.

$32.33+0.50%51

ENOVEnovis Corporation

$24.42+16.90%42

Bone Biologics (BBLG) in three numbers

Quality score: 21/100; Best check: net debt, -$6M. Weakest: return on capital, -47.8%.; Quality
Dividend: None; No dividend in the SEC filings we hold.; Dividends
P/E: -5.78; Negative: a loss over the last twelve months. Price to free cash flow -0.46.; Financials

Questions about Bone Biologics

Is Bone Biologics a high-quality business?

Bone Biologics scores 21 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from SEC filings. Its best check is net debt at -$6M, and its weakest is return on capital at -47.8%. The Quality tab shows every check against its target.

Does Bone Biologics (BBLG) pay a dividend?

No. Bone Biologics (BBLG) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 26 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in BBLG's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BBLG

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.